Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Total Non-Current Liabilities data on file, last reported at $517.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 441.19% year-over-year to $517.7 million; the trailing twelve-month figure through Mar 2026 stood at $517.7 million (up 441.19% YoY), and the FY2025 full-year result was $526.8 million, up 548.99% from the prior year.
• Total Non-Current Liabilities retreated to $517.7 million in Q1 2026, from $526.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $526.8 million in Q4 2025 to a low of $57.7 million in Q3 2023.
• A 5-year average of $192.6 million and a median of $105.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities plunged 72.85% in 2023 and jumped 548.99% in 2025, its largest moves.
• Tracing LGND's Total Non-Current Liabilities over 5 years: stood at $137.4 million in 2022, then tumbled by 57.4% to $58.5 million in 2023, then soared by 38.65% to $81.2 million in 2024, then jumped by 548.99% to $526.8 million in 2025, then fell by 1.73% to $517.7 million in 2026.
• Business Quant data shows LGND's Total Non-Current Liabilities at $517.7 million in Q1 2026, $526.8 million in Q4 2025, and $506.7 million in Q3 2025.